Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
| Autor: | Al-Samkari H; Hematology Division, Massachusetts General Hospital, Boston, MA 02139, USA. Electronic address: hal-samkari@mgh.harvard.edu., B Bussel J; Division of Hematology and Medical Oncology and Division of Pediatric Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA., Miyakawa Y; Department of Hematology, Saitama Medical University Hospital, Saitama, Japan., Broome CM; Lombardi Cancer Center, Division of Hematology, Georgetown University, Washington, DC, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Lancet (London, England) [Lancet] 2024 Aug 03; Vol. 404 (10451), pp. 434. |
| DOI: | 10.1016/S0140-6736(24)01263-7 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|